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ABSTRACT
Introduction: Type 2 diabetes mellitus (T2DM) is 
associated not only with high direct healthcare 
costs, but also with indirect costs, as diabetic 
complications and the disease itself result in loss 
of productivity. Vildagliptin is a novel dipeptidyl 
peptidase-4 inhibitor that is given either alone or 
in combination with oral hypoglycemic drugs, 
including metformin. The study was designed 
to assess the hypothesis that fixed-combination 
vildagliptin/metformin improves work 
productivity measured as Work Productivity and 
Activity Impairment (WPAI) scores. Secondary 
objectives were the assessment of patient 
satisfaction by means of the Diabetes Treatment 
Satisfaction Questionnaire (DTSQs), the change 
in anthropometric measurements and in glucose 
control (glycated hemoglobin [HbA1c]), and the 
evaluation of resource utilization (Resources 
Utilization Questionnaire). 
Methods: This study was an addendum to a 
mandatory, prospective, observational study carried 
out by the Italian Medicines Agency (Agenzia 
Italiana del Farmaco [AIFA]) in 49 diabetes centers 
in Italy. The addendum included 1,046 adult 
outpatients with a diagnosis of T2DM, who were 
no longer responding to metformin monotherapy. 
Patients were observed for up to 1 year. 
Results: Mean activity impairment improved by 
40.6% (15.4 ± 17.4 vs. 26.1 ± 24.4; P < 0.0001), 
absenteeism by 49.9% (2.0 ± 9.4 vs. 3.8 ± 13.3; 
P = 0.0076), and total work productivity by 37.6% 
(14.9 ± 15.9 vs. 21.5 ± 24.6; P < 0.0001). This 
resulted in a reduction of the annual indirect 
cost due to impaired productivity of €400 per 
working patient and €135 per patient in general. 
The DTSQ score increased by 30.2% (29.6 ± 
5.6 vs. 22.8 ± 6.9; P < 0.0001). The satisfaction 
rate increased from baseline by 44.7%; the 
hyperglycemia-free or almost hyperglycemia-free 
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study showed that both patients with T2DM and 
their carers lose income, especially when the 
patients experience diabetic complications [5]. 
According to the CODE-2 study, overall indirect 
costs of absenteeism related to diabetes in Italy 
amount to €234 million [6].
According to international guidelines, 
the management of T2DM includes the 
implementation of a healthy lifestyle, the 
introduction of metformin, which has proved to 
be able to reduce the risk of diabetic complications 
and death, and the use of other pharmacological 
options, as most patients require the addition of 
a second oral antidiabetic drug [7–9]. 
Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) 
inhibitor that has proved to be effective 
in reducing glycated hemoglobin (HbA1c)
without weight gain and with minimal 
hypoglycemia, when it is given as monotherapy 
or in combination with the most commonly 
prescribed classes of oral hypoglycemic drugs, 
including metformin [10, 11]. Both vildagliptin 
and fixed-dose combination vildagliptin/
metformin have been approved for therapeutic 
use in T2DM in the European Union and in 
various other countries.
In February 2008, a mandatory observational 
study monitoring the efficacy, tolerability, 
and safety profile of novel antidiabetic drugs 
for T2DM, including vildagliptin, in clinical 
practice for at least 1 year was started by the 
Italian Medicines Agency (Agenzia Italiana 
del Farmaco [AIFA]) [12]. This study derived 
from an addendum to the AIFA protocol and 
was designed to assess the hypothesis that 
fixed-combination vildagliptin/metformin 
improves work productivity measured as Work 
Productivity and Activity Impairment (WPAI) 
scores in the cohort of patients treated with the 
fixed combination after 1 year of treatment. 
Secondary objectives were the assessment of 
patient satisfaction by means of the Diabetes 
perception rate by 37.9%; and the hypoglycemia-
free or almost hypoglycemia-free rate by 15.2%. 
Mean healthcare costs per patients diminished 
by 19.2% in the second semester of treatment. 
Conclusion: This observational study suggests 
that the fixed combination of vildagliptin/
metformin increases work productivity, 
reducing indirect costs, and improves quality of 
life, especially in terms of perception of blood 
glucose variability, in patients with T2DM. 
Keywords: Fixed combination; Healthcare 
costs; Metformin; Patient-reported outcomes; 
Productivity; Resources; Type 2 diabetes mellitus; 
Vildagliptin 
INTRODUCTION
European and US studies have shown that 
patients with type 2 diabetes mellitus (T2DM) 
account for 3–5% of the total population, but 
consume up to 15–20% of total healthcare 
resources [1]. According to the European CODE-2 
(Costs of Diabetes in Europe-Type 2) study [2], 
the reason for this is frequent hospitalizations 
due to diabetic complications, which account 
for more than half of the healthcare costs (55%) 
due to diabetes. The situation is alarming for 
healthcare budgets as the worldwide prevalence 
of T2DM is continually increasing: the World 
Health Organization (WHO) has estimated that 
it amounted to 171 million patients in 2000 and 
will more than double over 30 years, reaching 
366 million in 2030 [3].
Diabetes is associated also with indirect costs, 
as diabetic complications reduce the patient’s 
ability to work, resulting in loss of productivity 
and need for social service support. The Centers 
for Disease Control in the US have estimated 
that patients with diabetes lose on average 
8.3 days of work per year versus 1.7 days per year 
for patients without diabetes [4], and a European 
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data (HbA1c), patient satisfaction data (DTSQ 
status scores), resource utilization (Resources 
Ut i l i za t ion Quest ionnai re  outcome) , 
exposure to the fixed combination, and study 
completion status.
The WPAI [14] is a six-item questionnaire 
aimed at evaluating the impact of a disease 
on absenteeism rate and work productivity 
over the last 7 days; it is completed by the 
patient. Four scores were derived from it: 
absenteeism (% work time missed due to ill 
health, calculated as Q2/[Q2+Q4]), activity 
impairment (% activity impairment due 
to ill health, calculated as Q6/10), work 
productivity score (% overall work impairment 
due to health, calculated as [Q2+Q4×Q5/10]/
[Q2+Q4]), presenteeism (% impairment 
while working due to health, calculated as 
Q5/10). However, considering the main study 
endpoint, presenteeism was not evaluated 
among the primary nor secondary variables, 
due to its lower impact on the NHS. For all the 
above scores, higher numbers indicate greater 
impairment and less productivity. 
For the WPAI questionnaire, WPAI General 
Health (WPAI-GH) domains calculation, the 
following statements were adopted: if a patient 
declared not to be employed (Q1 = 0), the 
remaining items dealing with work aspects 
(i.e., Q2, Q3, Q4, and Q5) were considered 
as missing values. If a patient declared not 
to be employed (Q1 = 0) but even one item 
concerning work aspects (Q2, Q3, Q4, Q5) was 
compiled with a positive value >0, the patient 
was assumed to be employed (i.e., the Q1 answer 
was assumed to be 1). If a patient declared to 
be not employed or had Q1 missing value, 
and both Q2 and Q4 were = 0, the patient was 
assumed not to be employed (i.e., the Q1 answer 
was assumed to be 0). If a patient declared to 
be employed, the following consistency rules 
among work-answers were checked:
Treatment Satisfaction Questionnaire (DTSQs), 
the change in anthropometric measurements 
and in glucose control (HbA1c) after 1 year 
of treatment, and the evaluation of resource 
utilization (Resources Utilization Questionnaire).
MATERIALS AND METHODS
The study was a prospective, observational, 
multicenter study. Inclusion criteria were the 
following patient characteristics: adults with 
a diagnosis of T2DM, who were no longer 
responding to metformin monotherapy and to 
whom National Health Service (NHS) physicians 
prescribed fixed-combination vildagliptin/
metformin as a second step according to AIFA 
Registry on innovative drugs (incretin mimetics 
and DPP-4 inhibitors). This occurred during the 
monitoring period set by AIFA, in compliance 
with the recommendations described in the 
Summary of Product Characteristics [13]. The 
exclusion criteria were as follows: patients who 
were not able to complete the questionnaire 
independently, who had been taking any DPP-4 
inhibitors for more than 1 month, and who 
required three or more antidiabetic drugs, or 
were using insulin.
Forty-nine NHS diabetes centers in Italy 
took part in the study, which was conducted in 
compliance with the decree on observational 
studies of March 2008 issued by AIFA and other 
relevant legislation. Patients had to give their 
informed consent to collection and use of the 
data in writing. The study was approved by local 
ethics committees.
The data collection included the following: 
demographic information (age, gender, ethnic 
group), anthropometric details (body weight, 
height, waist circumference, and calculation of 
body mass index [BMI]), medical history (date 
of diagnosis of T2DM, concomitant diseases), 
loss of productivity (WPAI scores), efficacy 
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•	 If Q4 (number of working hours during 
the last 7 days) = 0, the value of the 
Q5 item (patient’s productivity affected 
while working) was assumed to be missing.
•	 If Q2 (number of hours missed because 
of ill health), Q3 (number of hours 
missed because of other reasons), and Q4 
(number of hours worked) items values 
were missing or = 0, all the items Q2, Q3, 
Q4, and Q5 were assumed to be missing, 
although the patient maintained his/her 
employed status. If Q2 and Q4 = 0 but 
Q3 > 0, all the values were, instead, 
considered as possibly representing the 
condition of an employed patient absent 
from his/her workplace for reasons other 
than ill health (e.g., on holiday).
•	 If Q2 (number of hours missed because of 
health problem) or Q3 (number of hours 
missed because of other reasons) were 
missing but the Q4 (number of hours 
worked) value was a positive number >0, 
the Q2 and Q3 answers were assumed 
to be 0 (i.e., it was assumed that the 
patient had been working for the last 
7 days).
For further details on each WPAI-GH question, 
see the Reilly Associated website [15].
DTSQ status [16] is an eight-item 
questionnaire, scored on a scale of 0–6, with 
the aim of assessing total diabetes treatment 
satisfaction and the perceived frequency of 
hyperglycemia and hypoglycemia (5–6 = very 
dissatisfied; 3–4 = dissatisfied; 1–2 = fairly satisfied; 
0 = very satisfied); it is completed by the patient. 
The Resource Utilization Questionnaire was 
completed by the physician in cooperation with 
the patient with the aim of assessing healthcare 
services utilization over the last 6 months 
and was subdivided into three areas: diabetic 
complications (cardiovascular, cerebrovascular, 
renal, neurologic, and ophthalmic), laboratory 
tests and other diagnostic investigations, other 
resources used (emergency department, general 
practitioner [GP] consultations, specialist 
consultations, hospitalizations). In order to 
assign a monetary value to these services, the 
official national tariff list was used [17–19]. 
The annual number of hours lost from work 
due to the disease was calculated based on 
the results of the questionnaire filled in at 
baseline and at the end of follow-up to the 
1-year period. For nonworking patients, it was 
assumed in a conservative manner that the 
same proportion of patients would have lost 
the same average number of hours from their 
regular weekly activities due to the disease as 
the working population. It was assumed that 
the calculated annual number of hours lost 
from work at baseline was representative of the 
year before, whereas the result obtained at the 
12-month visit was representative of the 1 year 
of follow-up. In order to evaluate the annual 
cost of productivity lost due to the disease, 
the average annual number of hours lost from 
work by working patients was multiplied by 
the national average gross wage [20] per hour. 
The results were expressed as annual cost per 
working patient and annual cost per patient 
in general. 
The patients were monitored for 1 year at 
baseline, 6 months, and at 12 months or at 
premature discontinuation. DTSQ and WPAI 
data were collected at baseline, 6 months and 
12 months; the anthropometric and efficacy 
data at baseline and at 12 months; resource 
utilization at 6 and 12 months, referring to the 
previous 6 months. No baseline evaluation was 
available. The data other than DTSQ, WPAI, and 
resource utilization were already included in the 
AIFA monitoring project.
The data were collected on case report 
forms and the information was entered into 
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an electronic database by means of single 
data entry with electronic data verification. 
Textual elements (e.g., comments) were verified 
manually. The entered data were checked 
by means of validation programs and listing 
control. Obvious errors were corrected by data 
management personnel, whereas nonobvious 
errors and omissions that generated queries 
were sent to the investigators for resolution. 
Concomitant diseases were coded using 
the terminology of the Medical Dictionary 
for Regulatory Activities (MedDRA). Values 
for continuous measures for patients who 
discontinued prematurely or had missing values 
were handled with the last observation carry-
forward (LOCF) approach for analysis. When 
the database was declared to be completed and 
accurate, it was locked. 
Statistical Analysis
The statistical analysis was performed on all 
the patients treated with fixed-combination 
vildagliptin/metformin who had at least one 
post-baseline observation by Opis Srl (Desio, 
Italy), a clinical research organization, using 
SAS v. 9.1 (SAS Institute Inc., Cary, NC, USA). 
Demographic, anthropometric, efficacy, 
and resource utilization variables, as well as 
exposure, were analyzed descriptively, providing 
summary statistics for continuous variables 
and frequency tables for discrete variables. The 
mean changes in each calculated WPAI domain 
(higher numbers indicating greater impairment 
and less productivity) and in DTSQ satisfaction 
score (higher numbers indicating greater 
satisfaction) were analyzed by means of a paired 
t-test or signed-rank test (for non-normal data 
distributions). In addition, WPAI and DTSQ 
patients’ rates for each score level were provided.
In order to reduce the impact of missing 
values on study results, the main efficacy 
analyses were performed both according 
to prevalence approach and according to 
LOCF approach. A sensitivity analysis was 
performed on those evaluable patients with 
both baseline and 12 month visit information 
with descriptive meaning.
The sample size was calculated on the basis 
of WPAI, which included three measures, so the 
Bonferroni adjustment method [21] was applied 
to safeguard the overall statistical significance 
level. Setting the alpha level at 5%, power at 
80%, and assuming that the mean change after 
52 weeks would range from –3.0 to –2.2 with 
a standard deviation between 21.7 and 23.0 on 
the basis of previous experience, a sample size 
of about 1,000 patients was required. With a 
sample size of 1,000 patients, the power was 
97% for absenteeism, 83% for work productivity, 
and 80% for activity impairment.
RESULTS
A total of 1,046 patients were monitored and 
the majority of them (906 [86.6%]), completed 
the study. Sixty-one of the 140 patients who 
did not complete the 12 months of observation 
had valid post-baseline data, which were 
carried forward up to the 12th month. Hence, 
967 patients were included in the analysis. 
Out of the 140 patients who did not complete 
the study, 57 (5.5%) withdrew their informed 
consent and 83 (7.9%) were lost to follow-up. 
Mean ± SD exposure to the fixed combination 
was 11.7 ± 1.1 months.
The patients were mostly Caucasian (98.6%); 
nearly all the remaining patients were Asian 
(1.1%). The population included patients of all 
ages, ranging from 28 to 88 years of age, but most 
of them were middle-aged (46–65 years; 62.1%) or 
elderly (>65 years; 30.6%); 60.9% were of working 
age, but only 36.6% were actually working. 
Slightly more patients were male (57.7%). 
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On average, they had been diagnosed with T2DM 
7.7 ± standard deviation (SD) 6.7 years earlier; most 
of the patients had been diagnosed no more than 
10 years earlier (74.4%). More than 50% of the 
patients (52.8%) had concomitant diseases: the 
most common were vascular disorders (72.3%; 
mainly hypertension 70.8%), metabolism and 
nutrition disorders (42.8%, mainly dyslipidemia 
19.2%, hypercholesterolemia 12.1%, and obesity 
10.7%), and heart disease (12.7%, mainly 
ischemic heart disease 6.3%). 
All the three WPAI domains improved 
significantly after 1 year of treatment. Mean 
activity impairment improved significantly 
by 40.6% (P < 0.0001). At baseline a total of 
367 patients were actually working (36.6%), 
and could provide absenteeism and total work 
productivity data; after 1 year absenteeism 
improved significantly by 49.9% (P = 0.0076, 
n = 248) and total work productivity score 
improved significantly by 37.6% (P < 0.0001, 
n = 244). Major improvement was already 
recorded after 6 months of treatment (Fig. 1). 
The LOCF approach yielded similar results. The 
average number of hours per week reported to be 
lost due to diabetes decreased by 46% at the end 
of follow-up (1.64 vs. 0.63). At baseline, 11.7% of 
working patients reported to have lost due to the 
disease on average 11.4 hours in the last week. At 
the end of follow-up 9.8% of working patients 
reported to have lost on average 6.1 hours in 
the last week due to the disease. The number of 
hours lost per patient due to illness during the 
previous year was 59, with a reduction of 56% 
in the year of follow up, resulting in 26 hours 
lost per patient (Table 1). In monetary terms, 
considering only the wage of working patients, 
there was a 55% reduction equivalent to €400.15 
(€721.13 vs. €321.98) on average per employed 
patient. Considering all patients (both working 
and nonworking) the average reduction was 53% 
equivalent to €134.85 (€253.1 vs. €118.17) per 
patient (Table 2).
The mean (SD) TTS score increased 
significantly by 30.2% (29.6 ± 5.6 vs. 22.8 ± 6.9; 
P < 0.0001) after 1 year. The proportion of 
patients who were very satisfied with treatment 
increased from baseline by 44.7%, those who 
perceived themselves as hyperglycemia-free or 
almost hyperglycemia-free by 37.9%, and those 
who perceived themselves as hypoglycemia-free 
or almost hypoglycemia-free by 15.2% (Fig. 2). 
A post-hoc analysis comparing activity 
impairment status (worsened, i.e., change vs. 
baseline >0; stable, i.e., change vs. baseline = 0; 
improved, i.e., change vs. baseline <0) with the 
perception of hypoglycemia (worsened, stable, 
improved) showed that there was a statistically 
significant association between stable and 
improved activity impairment and stable or 
improved perception of hypoglycemia (chi-square 
P < 0.0001). Activity impairment and perception 
Fig. 1  Work Productivity and Activity Impairment 
Questionnaire: General Health (WPAI-GH): bar chart 
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of change in hyperglycemia were both either 
stable or improved in 73% of patients.
The anthropometric measures improved 
during the 1 year of treatment in women, but 
remained almost the same in men: mean ± SD 
waist circumference diminished by –1.8 cm in 
women (102.1 ± 12.9 cm vs. 103.5 ± 13.5 cm at 
baseline) and by –0.6 cm in men (103.7 ± 11.5 cm 
vs. 104.5 ± 11.3 cm at baseline); mean body weight 
diminished by –4.2 kg in women (77.8 ± 15.5 kg 
vs. 79.3 ± 16.2 kg), whereas it increased by +1.2 kg 
in men (85.5 ± 14.6 kg vs. 86.3 ± 15.0 kg at 
baseline); also BMI diminished by –1.3 kg/m2
in women (29.1 ± 6.8 vs. 31.6 ± 6.2 at baseline) 
whereas it increased by +0.7 kg/m2 in men (31.2 ± 
6.3 vs. 29.6 ± 4.6 at baseline).
Table 1  Indirect costs: h of productivity lost
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Aer 1 year of treatment the annual number of h per patient missed for the disease management decreased by 56%
11.7% of patients (n = 123) lost on average 501 h in the year before and 206 h during the 1-year follow-up
Table 2  Indirect costs: the cost of productivity loss
Baseline Month 12 Dierence (%)
Total cost of productivity lost €264,652.96 €114,268.00 –€150,384.96
Number of employed patients





Number of patients (all)





Indirect cost per patient per year has decreased by 53% at the end follow-up
Indirect cost per employed patient per year has decreased by 55% at the end follow-up
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Efficacy expressed as HbA1c improved with 
the fixed combination in 54% of patients 
and remained stable in 41%. Mean HbA1c 
diminished by 0.9% from 8.0 ± 1.2% down to 
7.1 ± 0.9%. There was no important difference 
between genders and BMI.
In total, 20 patients (2.2%) were admitted 
to hospital: 16 because of complications and 
4 because of unsatisfactory glucose control. Nearly 
all the patients (96.5%) had laboratory and/or 
other diagnostic tests, on average 22.3 per patient 
during the 1 year follow-up. In particular, nearly 
all the patients were prescribed HbA1c (96.3%; 
mean number 2.8), fasting blood sugar (91.6%; 
mean number 8.9), and alanine aminotransferase/
aspartate aminotransferase (ALT/AST; 95.6%; 
mean number 2.7). Most patients were prescribed 
high-density lipoprotein/low-density lipoprotein 
(HDL/LDL) cholesterol (87.8%; mean number 
2.2), triglycerides (87.8%; mean number 2.2), 
complete urinalysis (82.0%; mean number 2.3). 
Other commonly prescribed tests were uric acid 
(60.7%; mean number 1.8) and microalbuminuria 








































































































Fig. 2  (a) Proportion of patients by extent of satisfaction 
with current treatment expressed as a score on a six-
item semiquantitative rating scale. (b) Proportion 
of patients by perception of hyperglycemic episodes 
expressed as a score on a six-item semiquantitative 
rating scale (c) Proportion of patients by perception of 
hypoglycemic episodes expressed as a score on a six-item 
semiquantitative rating scale
(c)
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804 patients (80.2%) used additional resources, 
on average 6.2 times: 65.7% of patients consulted 
their GP on average 3.5 times, 60.5% consulted 
a specialist on average 2.8 times, an average of 
1.5 additional investigations (instrumental 
exams/tests) were prescribed to 17.4% patients, 
and 2.6% of patients went to an emergency room 
on average 1.3 times.
The mean healthcare cost per patient 
diminished from €130.22 during the first semester 
to €105.28 in the second semester (–19.2%); the 
annual cost per patient was €225.33. Resource 
breakdown showed that all the kinds of resources 
considered diminished, reductions ranging from 
–15.3% (laboratory tests and investigational 
procedures) to –23.2% (hospitalizations; Fig. 3). 
DISCUSSION
Incretin mimetics are innovative drugs for oral 
treatment of T2DM and their recent introduction 
into clinical practice would be expected to have 
a negative impact on diabetic therapy costs.
This study shows that the use of fixed-
combination vildagliptin/metformin for 
1 year is associated not only with a significant 
improvement in work productivity (+40.6%), but 
also with an annual reduction in indirect costs 
of €400.15 per working patient and of €134.85 
per patient in general. It also shows that the use 
of the fixed combination is associated with an 
improvement in quality of life, as measured by 
the DTSQ questionnaire (+30.2%), particularly 
in terms of perception of excessive changes in 
blood glucose levels (hyperglycemia +37.9%, 
hypoglycemia +15.2%); these perceptions are 
supported by an objective improvement in 
HbA1c in 54% of patients and stabilization of 
HbA1c in 41%. An estimate of healthcare costs 
per patient suggested that the use of fixed-
combination vildagliptin/metformin actually 
reduces such costs, as they diminished on 
average by 19% during the second semester of 
treatment. The results related to productivity 
and quality of life applies to all countries. 
The estimates of costs may vary from country 
to country, but the outcome that healthcare 
expenditure tends to diminish should apply 
everywhere. 
The results of the present study are 
consistent with the outcome of a survey in 
1,404 respondents by the Brod group, who 
established that nonsevere hypoglycemic events 
are associated with lost productivity estimated 
to range from $15.26 to $93.47 per event and 
from 8.3 to 15.9 hours of lost work time per 
month [22].
To the authors’ knowledge, no other studies 
have provided data on the impact of fixed-
combination vildagliptin/metformin on work 
productivity and indirect cost saving using 
WPAI, or on patient satisfaction measured by 
DTSQ. Thus, the strength of the study is that 
it has provided additional original information 
























Fig. 3  Comparison of the mean costs per patient during 
the rst and second semester of treatment in Euros
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global impact of chronic antidiabetic treatment 
with fixed-combination vildagliptin/metformin 
on the life of the patient.
Extensive data have already been provided 
on the efficacy of the vildagliptin/metformin 
combination in reducing HbA1c, which are 
consistent with the results in this study (–0.6 to 
–1.8% vs. –0.9% in the present study) [23–26]. 
The finding of improved satisfaction with 
treatment and improved HbA1c is consistent 
with the outcome of a study on quality of life 
in 2,500 outpatients with T2DM, which found 
that improvement in HbA1c and the use of 
oral antidiabetic agents only were amongst the 
factors that contributed to better quality of life, 
particularly to higher treatment satisfaction as 
measured by DTSQ [27].
The assessment of utilization of healthcare 
resources other than drugs and the consequent 
cost for patients with T2DM treated with 
the fixed combination suggested that the 
introduction of the new antidiabetic product 
did not increase healthcare resource utilization 
and related costs; on the contrary it appeared to 
reduce it. The estimate of annual cost per patient 
of €225.00 is lower than the annual cost per 
patient (€320.00–€340.00) reported in an Italian 
study [28]. The reason for this difference may 
lie in differences in the patient population, as 
Garattini et al. included also patients on insulin, 
who may experience more complications. 
The assessment of direct healthcare costs is 
lower also than in previous observational 
studies [29]. As the study did not consider the 
cost of drugs, it is not fully consistent with a 
previous assessment of the economic impact 
of the introduction of vildagliptin, both alone 
and in fixed combination with metformin, 
on healthcare expenditure for T2DM patients 
in Italy [30]. This assessment ascertained that 
the introduction of vildagliptin involved an 
increase in pharmaceutical costs that was offset 
by a reduction in the management costs of 
serious or severe adverse events (which were 
fewer as specified below and documented 
in the Periodic Safety Update Reports on 
metformin, vildagliptin) [31] and in therapeutic 
monitoring. Nevertheless, the outcome was that 
introduction of the fixed combination produced 
an overall increase in healthcare expenditure 
by 1.48%, a modest increase, but not no 
effect at all or even a reduction as this study 
suggests. Failure to consider the cost of drugs, 
which makes this study not fully consistent 
with previous investigations, is a limitation of 
this study. 
Fewer adverse events are the result of the 
good tolerability profile of fixed-combination 
vildagliptin/metformin. Safety and tolerability 
were assessed according to the regulations 
in force and the recommendations in the 
summary of product characteristics within the 
context of the study conducted by AIFA on 
innovative antidiabetic drugs, of which this 
study is an addendum. The AIFA study was an 
important component of the usual mandatory 
pharmacovigilance plan for medicinal products 
that have been recently introduced into clinical 
practice. From January 2009 to July 2011 only 
69 adverse reactions were reported in the whole 
patient population given the fixed combination 
(n = 21,483 patients). Of the 69 reactions, only 
12 (0.06%) were serious [31]. This is consistent 
with the outcome of this study, in which only 
20/906 patients (2.2%) were hospitalized because 
of serious adverse events. Consequently, the 
fixed combination is also well tolerated in real-
life clinical practice; its safety and tolerability 
profile may be considered to be reliable. 
The good tolerability profile of fixed-
combination vildagliptin/metformin may 
explain the low assessment of costs: a survey in 
more than 20,000 adult patients with T2DM on 
treatment with oral antidiabetic agents and not 
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insulin, as in this study, showed that there is 
an inverse association between productivity (as 
measured by WPAI) and tolerability [32].
The hospitalization rate was particularly 
low in this study (2.2%), because it included 
only adult patients suffering from type 2 
diabetes mellitus that was not severe and was 
well controlled by oral antidiabetic therapy. 
The study excluded patients on insulin, who 
experience the most complications and who 
consume the most resources. This is a weakness 
of the study and may account for the particularly 
low estimation of resource utilization costs, 
resource consumption, and related annual cost 
per patient.
CONCLUSION 
This observational study suggests that the 
fixed combination of vildagliptin/metformin 
increases work productivity, reducing indirect 
costs, and improves quality of life, especially 
in terms of perception of changes in blood 
glucose, in patients with T2DM. This additional 
information should be taken into consideration 
for the overall evaluation of the clinical impact 
of the combination. 
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